Skip to main content
. Author manuscript; available in PMC: 2012 May 1.
Published in final edited form as: Mol Cancer Ther. 2011 Mar 3;10(5):795–805. doi: 10.1158/1535-7163.MCT-10-0936

Figure 2. (−)-Gossypol suppresses tumor growth and angiogenesis of human prostate tumor xenografts.

Figure 2

PC-3 cells were injected into 5- to 6-week-old BALB/cA nude mice (5×106 cells per mouse). After solid tumors established, the mice were subcutaneously treated with or without (−)-gossypol at dosage of 15 mg/kg daily. A, (−)-gossypol inhibited tumor growth as measured by tumor volume. B, the weight of solid tumors in the (−)-gossypol-treated mice was significantly lower than that of the control group. C, anti-CD 31, anti-VEGF and anti-VEGFR2 immunohistochemistry revealed that (−)-gossypol inhibited neovascularization and VEGF expression in solid tumors. D, microvessel density was analyzed by Image-Pro Plus 6.0 software. Columns, mean; bars, standard error; *, P < 0.05 vs. the control group.

HHS Vulnerability Disclosure